Skip to content
iMediSync logo — AI-DRIVEN EARLY DETECTION THERAPEUTIC PLATFORM FOR OPTIMAL B...

iMediSync

AI-DRIVEN EARLY DETECTION THERAPEUTIC PLATFORM FOR OPTIMAL BRAIN HEALTH

Founded 2012 Korea South Korea South 10 employees Series C Total: $15.60B Analytics, Health Care

General Information

Company Name iMediSync
Founded Year 2012
Location Korea South Korea South
Founders / Decision Makers
Team member
Employees 10
Industries Analytics, Health Care
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with iMediSync. To contact iMediSync, visit imedisync.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does iMediSync compare?

A PDF of iMediSync and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting iMediSync soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About iMediSync

is an AI-driven early detection therapeutic platform for optimal brain health, founded in 2012. Originating from the National Standard Data Center for Korean EEG at Seoul National University, it has developed Asia’s first QEEG normative DB with over 1300 healthy subjects aged 4–90. The platform's flagship product, iSyncBrain®, is an AI-driven analysis cloud platform registered as a class II medical device by the Korean FDA and utilized in over 30 countries. The company's iSyncBrain – MCI Classifier received clearance from the Korean FDA as a class II medical device, with sensitivity and specificity each over 90%, after being clinically validated with three Korean university hospitals. The iSyncHeart® solution, a cloud-based AI for heart rate variability, has also been registered as a class II medical device by the Korean FDA and utilized for remote ECG monitoring in clinical trials. The platforms are primarily used by doctors and clinical psychologists for research and will expand for virtual telemental care. In January 2022, the company secured a KRW7.60B Series C investment from Widwin Investment and K-Len Ventures. iMediSync's vision is to develop early detecting biomarkers for challenging neurological disorders including Parkinson’s disease, TBI, PTSD, ADHD, and Depression.

Business keywords: AI-driven, Brain Health, Medical Device, Neurological, Digital Health, Mental Health, Biotech, AI Platform, Biomarker, EEG Analysis, Heart Rate Variability, Telemental Care, Diagnosis, Cloud Platform, Early Detection

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series C KRW7.60B 2
Widwin Investment, K-Len Ventures
27 Jan 2022
Series B KRW5.00B 2
ACE Ventures, KDB Bank Europe
13 Mar 2020
Series A KRW1.00B 1
Aju IB Investment
02 Jul 2018
Series A KRW2.00B 1
NHN Investment
13 Mar 2018
Seed Round Undisclosed 1
K-Run Ventures
20 Jul 2017
Seed Round Undisclosed 1
K-Run Ventures
18 Aug 2016

iMediSync Alternatives & Competitors

View All Alternatives
iMediSync vs

Technology-driven early-stage detection and therapeutic support tools for ADHD, ASD, Alzheimer's Dis...

Venture round
16 employees
AI, Analytics
iMediSync vs
Caspar.AI
Caspar.AI United States

Health Platform for Early Detection of Diseases and Incidents. Transforming Health with Generative A...

Seed
13 employees
Analytics, Health Care
iMediSync vs
Walkky
Walkky United States

AI Platform for Cardiovascular Diagnosis

Non Equity Assistance
7 employees
Analytics, Health Care

FAQ About iMediSync

AI-DRIVEN EARLY DETECTION THERAPEUTIC PLATFORM FOR OPTIMAL BRAIN HEALTH
iMediSync was founded in 2012.
iMediSync is headquartered in Korea South.
iMediSync operates in Analytics and Health Care. Its work centres on AI-driven, Brain Health, Medical Device and Neurological.
iMediSync has approximately 10 employees.
iMediSync has completed 6 funding rounds, raising a total of $15.60B. The latest funding stage is Series C.
Top alternatives and competitors to iMediSync include Braingaze, Caspar.AI, Walkky, CorVista® Health, Powerful Medical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
iMediSync and Braingaze are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for iMediSync, https://bouncewatch.com/company/imedisync, updated 11 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout